Adagene Inc. ADAG
Adagene Inc. (Nasdaq: ADAG) is an oncology drug developer. Its lead program, ADG126 (muzastotug), is in Phase 2 for MSS metastatic colorectal cancer (with anti-PD-1). Its next catalyst on record is ADG138: Initiate first-in-human Phase 1 study in China (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ADG138 — Initiate first-in-human Phase 1 study in China (Q4 2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ADG126 (muzastotug) | MSS metastatic CRC, combination with anti-PD-1 | antibody | Phase 2 |
| ADG116 | solid tumors (anti-CTLA-4) | antibody | Phase 1 |
| ADG138 | HER2-expressing advanced solid tumors | antibody | Pre-clinical |
| XB404 (Exelixis-partnered SAFEbody ADC) | ROR1/2 tumors | antibody | Pre-clinical |
Recent results and decisions
- Sep 22, 2026n/a China NMPA cleared the IND for ADG138, a HER2xCD3 double-masked T-cell engager (ex-US regulator).
China’s National Medical Products Administration (NMPA) has approved the company’s investigational new drug (IND) application for ADG138
Filing - Apr 17, 2026positive AACR interim: triplet ORR 66.7% (4/6) vs 32.5% (13/40) for atezolizumab+bevacizumab control (HCC mRECIST); small n.
Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%, respectively by Investigator per HCC-specific Modified RECIST v1.1)
Filing - Apr 1, 2026positive Recap of ASCO 2025 data: 29% (6/21) confirmed ORR at 20 mg/kg; mOS 19.4 months at 10 mg/kg; 4% discontinuation, no DLTs, no Grade 4/5 TRAEs across 67 patients.
As presented at ASCO 2025, muzastotug showed 29% (6/21) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.